Lenalidomid Sandoz (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, changing its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to reduced proliferation of malignant plasma and lymphoid cells, inhibition of angiogenesis, and enhanced immune‑mediated tumor clearance through increased natural‑killer cell activity and cytokine modulation.

The dosage of lenalidomide is individualized by the prescribing physician based on the specific indication, disease stage, renal function, and concomitant therapies. The prescriber determines the appropriate strength, schedule and duration, and patients should follow the exact dosing instructions provided on the prescription label and by their healthcare professional.

Lenalidomide is classified as having unknown pregnancy category and is known to be teratogenic in animal studies; therefore it should not be used by pregnant women and effective contraception is required for both men and women of child‑bearing potential. Limited data exist for breastfeeding, and the drug is generally avoided during lactation unless the benefit outweighs the risk.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming eligibility, then replies with pricing, availability, shipping details—including any temperature‑controlled logistics if needed—and the necessary import documentation.

The primary alternative to lenalidomide in many regimens is thalidomide, another immunomodulatory imide drug. Compared with thalidomide, lenalidomide generally shows a more favorable safety profile, with lower rates of peripheral neuropathy, and higher potency in targeting cereblon‑mediated pathways. Both agents share similar mechanisms but differ in pharmacokinetics, dosing schedules and specific adverse‑event spectra, influencing the choice of therapy based on patient tolerance and disease characteristics.

Lenalidomid Sandoz tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container to protect them from moisture and light. Do not refrigerate or freeze the product. Keep the medication out of reach of children and store it in a dry place away from direct sunlight to maintain stability and potency throughout its shelf life.

Lenalidomide is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water and should be taken at the same time each day to maintain consistent blood levels. Patients must follow the prescribed schedule, which may involve daily dosing for a set number of days followed by a rest period, depending on the treatment protocol.

The most serious risks include severe neutropenia and thrombocytopenia, which can predispose patients to life‑threatening infections and bleeding, as well as venous thromboembolism, especially when combined with corticosteroids. Additional concerns are the potential for secondary primary malignancies and rare but severe cutaneous reactions such as Stevens‑Johnson syndrome. Regular laboratory monitoring and prompt reporting of symptoms are essential to mitigate these risks.

Lenalidomide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. It should also be avoided in pregnant women and in individuals who cannot adhere to an effective contraception program. Patients with uncontrolled infections, severe hepatic impairment, or those receiving live vaccines may require alternative therapy or close monitoring, and the decision should be made by a qualified healthcare professional.